Prosecution Insights
Last updated: April 19, 2026

Toolgen Incorporated

6 pending office actions

Portfolio Summary

6
Total Pending OAs
2
Final Rejections
4
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
19317342 SINGLE BASE SUBSTITUTION PROTEIN, AND COMPOSITION COMPRISING SAME REGA, KYLE THOMAS 1636 Non-Final OA Sep 03, 2025
18467967 Compositions Comprising Cas9/guide RNA Complexes for Inducing Targeted Disruption of Endogenous Genes in Eukaryotic Cells HIBBERT, CATHERINE S 1658 Non-Final OA Sep 15, 2023
18313946 COMPOSITION FOR CLEAVING A TARGET DNA COMPRISING A GUIDE RNA SPECIFIC FOR THE TARGET DNA AND CAS PROTEIN-ENCODING NUCLEIC ACID OR CAS PROTEIN, AND USE THEREOF HIBBERT, CATHERINE S 1658 Non-Final OA May 08, 2023
17792203 CELLS HAVING HIGH ADAPTABILITY UNDER HYPOXIC CONDITIONS, AND USE THEREOF MATALKAH, FATIMAH KHALAF 1638 Non-Final OA Jul 12, 2022
17262342 GENE EDITING OF ANTICOAGULANTS MEYERING, SHABANA SHABBEER 1635 Final Rejection Jan 22, 2021
17004355 COMPOSITION FOR CLEAVING A TARGET DNA COMPRISING A GUIDE RNA SPECIFIC FOR THE TARGET DNA AND CAS PROTEIN-ENCODING NUCLEIC ACID OR CAS PROTEIN, AND USE THEREOF HIBBERT, CATHERINE S 1658 Final Rejection Aug 27, 2020

Managing Toolgen Incorporated's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month